Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2015

View Archived Issues

Novogen's brain tumor candidate TRXE-009 crosses BBB in animal studies

Vertex and Parion to develop ENaC inhibitors for cystic fibrosis and pulmonary diseases

R-Tech Ueno collaborates with Spanish institutions on new drug for cerebral infarction

BMS starts phase I/IIa trial of ADC in solid tumors

BeiGene initiates phase I study of BGB-A317 for advanced cancer

AYX-2 transcription factor decoy shows potential for the treatment of chronic pain

EC-1456 generally well tolerated in phase I trial

Regeneron advances two programs: REGN-475 and REGN-2222

Corcept Therapeutics patents GR modulators

Jazz Pharmaceuticals starts phase III program for JZP-110 in excessive daytime sleepiness

Actelion Pharmaceuticals reports TPH1 inhibitors

CRT and ICR scientists develop Raf kinase B inhibitors

Phase I data reported for angiogenesis inhibitor TAS-115

Pivotal Therapeutics starts phase IIa trial of omega-3 fatty acid therapy

Neurocrine Biosciences suspends two planned trials of NBI-77860

Lilly reports first human data for Notch signaling inhibitor LY-3039478

Global Blood Therapeutics reports Hb allosteric modulators

PlasmaTech obtains license to AAV gene therapy for juvenile Batten disease

BioMarin files for European approval of drisapersen for DMD

NCI selects Rexahn's RX-21101 for preclinical characterization program

Idera and MD Anderson collaborate to conduct trials of intratumoral IMO-2125

Probuphine noninferior to sublingual buprenorphine in phase III trial in opioid dependence

PNP Therapeutics gene-directed enzyme prodrug therapy granted FDA orphan designation

DalCor and Montreal Heart Institute to collaborate on phase III trial of dalcetrapib

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...